High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells

Journal Article**Author(s):**

Hildinger, Markus; Baldi, Lucia; Stettler, Matthieu; Wurm, Florian M.

Publication date:

2007

Permanent link:

<https://doi.org/10.3929/ethz-b-000066202>

Rights / license:

In Copyright - Non-Commercial Use Permitted

Originally published in:

Biotechnology Letters 29(11), <https://doi.org/10.1007/s10529-007-9441-3>

High-titer, serum-free production of adeno-associated virus vectors by polyethyleneimine-mediated plasmid transfection in mammalian suspension cells

Markus Hildinger · Lucia Baldi ·
Matthieu Stettler · Florian M. Wurm

Received: 6 March 2007 / Revised: 1 June 2007 / Accepted: 5 June 2007 / Published online: 17 July 2007
© Springer Science+Business Media B.V. 2007

Abstract Adeno-associated virus (AAV)-based vectors belong to the most promising gene transfer vectors in clinical studies. To provide vector for late-stage clinical trials as well as for a potential commercial phase, a scalable, cGMP-compliant process is required. Nearly all vector production protocols currently approved in Phase I clinical trials rely on AAV production in adherent HEK 293 cells in the presence of serum. In this study, we present a helper- and serum-free production method of AAV vectors in suspension-adapted HEK 293 cells. The method is based on plasmid transfection with 25 kDa linear polyethyleneimine. Compared to existing methods, our system is highly scalable as cells grow in suspension, does not require animal-derived products or the use of an exogenous virus (adenovirus or baculovirus) and yields genomic titers equal to those obtained in adherent HEK 293 cells in the presence of serum. Most importantly, work load and cost could be dramatically reduced in comparison to earlier methods, when comparing the production of equivalent

volumes of cell culture media. Thus, our protocol should appeal to both basic research laboratories and cGMP manufacturing units.

Keywords Adeno-associated virus · Gene therapy · GMP · Production · Serum-free · Suspension

Introduction

Recombinant adeno-associated viruses (AAV) hold much promise for human gene therapy (Samulski 2003; Mandel and Burger 2004; Li et al. 2005). In this study, we describe a cost and time effective, highly scalable, serum-free method for producing AAV preparations based on transfection of suspension adapted HEK 293 cells (Baldi et al. 2005). This technique does not require expensive, special equipment or consumables and is thus equally applicable to GMP-grade vector manufacturing as well as to bench research. Briefly, suspension-adapted HEK 293 cells, growing as single cells in defined, serum-free media, are transfected while maintained in suspension culture. Producer cells are harvested 2–3 days after transfection by a simple centrifugation step. Yields are comparable to those obtained with a standard protocol [e.g. adherent HEK 293 cells in media with 10% v/v FCS (Auricchio et al. 2001)].

Most protocols for larger-scale AAV production are based on stable cell lines (Maxwell et al. 1997; Liu et al. 2000; Gao et al. 2002; Farson et al. 2004) and/or

M. Hildinger · F. M. Wurm
ExcellGene S.A, Route de l'île-au-bois 1A, Monthey,
Valais 1870, Switzerland

L. Baldi · M. Stettler · F. M. Wurm (✉)
Institute of Biological Engineering and Biotechnology,
Laboratory of Cellular Biotechnology, Swiss Federal
Institute of Technology (EPFL), Lausanne 1005,
Switzerland
e-mail: florian.wurm@epfl.ch

viral infection (Conway et al. 1999; Booth et al. 2004; Li and Samulski 2005). Only few research groups have worked on AAV production in suspension cells but have pursued approaches that are different from our transfection-based protocol. For example, Farson et al. (2004) have described a process for producing AAV preparations in suspension cells without serum. Their method relies on a A549-derived stable producer cell line (which afterwards was adapted to suspension growth) and infection of that cell line with an adenoviral vector. In contrast, our method does not rely on a stable cell line; instead, all components required for AAV production are introduced into the producer cell by DNA transfection, which offers a higher degree of flexibility as the cap and rep sequences can be varied from preparation to preparation. In addition, Farson et al. created the producer cell first, and then adapted it to suspension growth.

Urabe et al. (2002) described a method for producing large quantities of AAV vectors in Sf9 (insect) cells. Sf9 cells grow in suspension, and serum is not essential for their growth. The system requires a baculovirus to introduce AAV packaging functions into the producer cells though adenoviral helper functions are not needed. Whereas this is an excellent system to produce AAV, there is the additional need of producing baculovirus. Furthermore, packaging constructs optimized for expression in mammalian cells have to be modified in order to achieve high-yield production in Sf9 cells, which could become a bottleneck if one works with some of the more recently identified serotypes.

Our simple, fast and scalable protocol represents an interesting alternative to existing AAV production systems based on mammalian cell transfection and should be attractive for GMP manufacturing and bench research.

Materials and methods

Unless otherwise stated, all experiments were performed in triplicates.

Plasmid constructs

The AAV2 packaging plasmid (pRepCap2), Ad helper (pHelper) plasmid and *cis* vector have been described (Stratagene 2004). The plasmid sequences

can be sent electronically upon request. Plasmid DNA was purified using the Giga Plasmid Preparation Kit (Qiagen GmbH, Hilden, Germany).

Vector production

Standard protocol

Our standard protocol for AAV production has been described (Auricchio et al. 2001). In short, for one AAV vector preparation, 50 15-cm dishes of subconfluent, low (<50) passage HEK 293 cells (ATCC, Manassas, VA) were transfected by calcium phosphate with 2.5 mg plasmid DNA (pHelper, pRepCap2, pAAV eGFP in the ratio 2:1:1). Medium was changed the following day, and cells were harvested 3 days after transfection and the virus isolated as previously described (Auricchio et al. 2001). We have also produced AAV virions in adherent HEK 293 cells using polyethylenimine (PEI) as transfection reagent (and a medium change 7 h after transfection). Titers were similar to those obtained with calcium phosphate (data not shown).

Suspension protocol

Expansion: Prior to transfection, suspension-adapted HEK293E cells (Durocher et al. 2000) were expanded in Ex-Cell 293 HEK 293 serum-free medium (JRH Biosciences, Lenexa, Kansas, USA, “Ex-Cell” medium) with 4 mM L-glutamine. Cells were cultured at 10^6 cells per ml up to 4×10^6 cells per ml. Splitting was done by pelleting the cells and resuspending them at the appropriate density in Ex-Cell medium. The day prior to transfection, cells were resuspended in fresh Ex-Cell medium at 10^6 cells per ml so that they are in their growth phase at the day of transfection. Cells were maintained in square-shaped glass bottles with a screw cap (Schott Glass, Mainz, Germany) with medium equal or less than 1/3 of the bottle volume and with agitation at 110 rpm on a model orbital shaker (Muller et al. 2005). Agitation is essential for our protocol to work in order to provide cells with sufficient O₂ to survive at the cell densities used; without agitation, cells will settle to the ground of the glass bottle and die.

Transfection: For transfection, cells were pelleted, washed once with phosphate buffered saline (PBS), and resuspended at 2×10^6 cells per ml in RPMI 1640 with 25 mM HEPES (pH 7.1) and 4 mM L-glutamine

(BioWhittaker Europe/Cambrex, Verviers, Belgium) and 1% Pluronic F68. The transfection cocktail was prepared as follows (quantities are per ml of resuspended cells): 7.5 μ l of a 1 μ g/ μ l solution of 25 kDa polyethyleneimine (PEI; Polysciences, Eppelheim, Germany; pH7) was added to 42.5 μ l 150 mM NaCl (pH7). Separately, 2.5 μ g of DNA was dissolved in 50 μ l 150 mM NaCl (pH7). Then, the DNA was added to the PEI solution and resuspended by pipetting up and down. The complex was incubated for about 8 min at room temperature, and then added to the cells. (The complex should be added after 6–10 min incubation; earlier or later times decrease transfection efficacy by a factor of up to 2—unpublished data.) In the standard protocol, the three plasmids pHelper, pRepCap2, pAAV eGFP were transfected in a ratio of 2:1:1. For small-scale preparations (up to 5 ml final volume), cells were grown in 6-well plates under agitation at 200 rpm at 37°C. For large-scale preparations, the cells—upon addition of the transfection cocktail—were transferred into a round-shaped Schott glass bottle with a screw cap and shaken at 120 rpm on an orbital shaker at 37°C. A CO₂ atmosphere is optional. Four hours after transfection, an equal volume of Ex-Cell medium was added (i.e., 1 ml Ex-Cell medium for each ml RPMI medium.) In case of larger scale transfections, the cells were transferred into a square-shaped Schott glass bottle (up to 300 ml into one 1 l bottle.) The cells were then propagated for 48 or 72 h under agitation and then harvested by centrifugation. In addition to Ex-Cell medium, we also evaluated Pro-293s-CDM in our small scale experiments (BioWhittaker, Cambrex BioSciences, Walkerville, MD, USA); yet, given that it resulted in lower titers compared to Ex-Cell, we performed all large scale experiments with Ex-Cell medium.

Vector characterization

Genomic titer

The genomic titer was determined via Quantitative Real-Time PCR using the QuantiTect SYBR Green PCR Kit (Qiagen GmbH, Germany) and an ABI 7900 RealTime System (Applied Biosystems) according to the manufacturers' instructions. Prior to the Real-Time PCR, recombinant vector preparation was pretreated with DNase I and RNase A (Fermentas

GmbH, Germany). The DNase and RNase were then heat-inactivated for 30 min at 65°C. After that, the recombinant vector preparations were treated with 50 μ g proteinase K (Fermentas GmbH, Germany) at 55°C for 30 min and 60°C for 30 min, and the proteinase K was subsequently heat-inactivated for 20 min at 95°C.

Functional titer

The functional titer was determined either by serial dilution or by fluorometry. For the serial dilutions, HEK 293 cells that had been transfected with pHelper were infected with 1:5 dilutions of AAV eGFP, and the read-out was done using a fluorescence microscope. For the fluorimetric assay, HEK 293 cells that had been transfected with pHelper were infected with AAV eGFP. The cells were then lysed by two rounds of freeze-and-thaw, and eGFP fluorescence was measured using a CytoFluor 4000 (MTX Lab Systems).

Results

Influence of medium composition on AAV yields

Medium composition is an essential factor in AAV production. It influences the cell cycle, apoptosis, promoter activities and many other factors that play a role in the AAV life cycle. Thus, we tested three different media (RPMI, Ex-Cell, Pro-293s) for cultivating transfected suspension-adapted HEK 293 cells in the production phase ("production medium"). We also analyzed combinations of those media, with and without fetal calf serum (see Materials and Methods). The results are summarized in Fig. 1 for AAV2 (similar results were obtained with AAV5).

As expected, AAV yields were the lowest in RPMI as it is the most basic medium tested. Using the defined media Pro-293s and Ex-Cell increased virus yield by 50% and 100%, respectively. Yet, to our surprise, the best results were obtained with a 1:1 mixture of RPMI and Ex-Cell (approximately 5-fold increase in virus yield over RPMI alone.) The composition of Ex-Cell is not published; however, we assume it to contain factors with a negative effect on AAV production—while promoting HEK 293 cell growth and viability; for example, we have observed

Fig. 1 For each medium to be tested, 4×10^6 cells were transfected in triplicates (4 ml final volume) as described in Materials and Methods using plasmids pHelper, pRepCap2, pAAV eGFP in a ratio of 2:1:1. About 4 h after transfection, cells were resuspended in the medium to be analyzed. Three days later, cells were harvested and virus isolated. Functional titer was determined by infecting adherent HEK 293 cells that have been transfected with pHelper. Three days after infection,

infected cells were lysed by two rounds of freeze-and-thaw, and the amount of GFP in the lysate was quantified using a Cytofluor. Genomic titer was determined by RealTime PCR. Data are shown as mean values relative to RPMI as production medium. The absolute titers in RPMI were 1.8×10^{12} (genomic) and 3.3×10^{11} (functional) per liter of culture medium, respectively

a negative impact of certain yeast peptones on AAV yields when added to the medium (unpublished data). The addition of serum during transfection had only a modest effect on AAV production: the functional titers increased by approximately 30%, the genomic titers were not significantly different. Thus, serum has no influence on the total number of AAV particles, but might have a positive effect on virus particle stability. The addition of soy peptones the day after transfection in the presence of serum resulted in an additional 30% increase in yield.

As for cell survival in the different production media, we did not see any significant differences; however, the cell number at time of harvest was about 30% lower in pure RPMI compared to the other media formulations used (cells normally do not divide within the first 36 hours after transfection).

Influence of PEI:DNA-to-cell ratio and packaging plasmids on AAV yields

We next analyzed the optimal ratio of PEI:DNA-to cell ratio for the transfection as well as some alternative packaging plasmids. The optimal PEI:DNA ratio of 3:1

has already been published (Baldi et al. 2005), and all experiments were performed using that ratio.

In a first experiment, we compared virus yields by leaving the amount of PEI and DNA constant and varied the cell density between 5×10^5 cells per ml and 8×10^6 cells per ml (see Fig. 2A). The optimal cell density for AAV production—according to our data—is 2×10^6 per ml. The decreased production at lower cell densities is most likely due to increased PEI toxicity (Florea et al. 2002) as there are now more PEI molecules per cell; at higher cell densities, production is decreased due to decreased transfection efficacy: Using pAAV eGFP alone one can clearly observe normal transfection efficacies at lower cell densities (yet, cell viability is decreased) and decreased transfection efficacies (lower eGFP expression) at higher cell densities (data not shown).

In a second experiment, we analyzed the influence of the amount of PEI:DNA on virus yields, leaving the PEI:DNA ratio constant at 3:1 (see Fig. 2B) $1.25 \mu\text{g}$ DNA/ml was the optimal ratio. Halving the amount of DNA decreased the virus yield by over 50%; on the other hand, increasing the amount of DNA had only a slightly positive effect (22%) on the functional titer. However, this effect was additive to

Fig. 2 For each condition tested, cells were transfected in triplicates as described in Materials and Methods in a total volume of 4 ml. Three days post-transfection, cells were harvested and virus isolated. Functional titer was determined by infecting adherent HEK 293 cells that have been transfected with pHelper. Three days after infection, infected cells were lysed by two rounds of freeze-and-thaw, and the amount of GFP in the lysate was quantified using a Cytofluor. **(A)** Data are shown as mean values relative to the expression obtained at a cell density of 2×10^6 cells/ml at the time of transfection. **(B)** Data are shown as average percentage change in GFP

expression with GFP expression at $1.25 \mu\text{g DNA/ml}$ (1x) as reference (0.5x: $0.625 \mu\text{g/ml}$; 2x: $2.5 \mu\text{g/ml}$). **(C)** Data are shown as average percentage increase in GFP expression relative to the expression obtained with the standard protocol (plasmids pHelper, pRepCap2, pAAV eGFP in a ratio of 2:1:1; growth in RPMI:Ex-Cell medium; no serum added). The absolute functional titers were 4.1×10^{11} (2a; 100%), 3.5×10^{11} (2b; 1x) and 3.7×10^{11} (2c; standard with a genomic titer of 2.1×10^{12}) per liter of culture medium, respectively

the serum effect, i.e., using $2.5 \mu\text{g DNA/ml}$ the amount of DNA in the presence of serum resulted in an overall titer increase of about 50%. Yet, even with the added serum effect, it is more economical to leave the DNA concentration at $1.25 \mu\text{g/ml}$ and double the production volume, which—given the scalability of the system—does not significantly increase the work load.

In a third experiment, we evaluated a different DNA cocktail for AAV production. Capsid formation is the rate-limiting step in AAV production (Vincent et al. 1997). Thus, we decided to execute a quadruple transfection of pAAV2 eGFP, pRepCap2, pHelper and pCMV Cap in a ratio of 1:1:1:1 (see Materials and Methods), where the Cap ORF is expressed under the control of the CMV promoter. The results are depicted in Fig. 2C. Interestingly, titers increased by roughly 40% through the addition of pCMV Cap. In the presence of serum, the functional titer nearly doubled, most likely due to further increased Cap expression (the CMV promoter is serum responsive (Brightwell et al. 1997) and unpublished data).

Effect of harvest time on AAV yields and infectivity

As an additional factor in AAV production, we evaluated the effect of harvest timing on AAV yields, i.e. the timing between transfection and discontinuation of the cell culture. Our hypothesis was that

genomic titers would increase with time (as more particles accumulate in the nucleus) but functional titers could decline due to “storage” in the nucleus. Thus, we compared an AAV harvest 2 days after transfection with an AAV harvest three days after transfection (Fig. 3A). The data confirmed our initial hypothesis: whereas 3 days of production increased the genomic titer by approximately 100% compared to 2 days of production, functional titers were approximately 30% higher when the cells were harvested after 2 days. In other words, whereas the ratio of genomic to infectious particles was approximately 10:1 after 2 days of production, it deteriorated to 26:1 after 3 days of production (data not shown). Thus, for optimal yields of infectious particles, a production period of two days should be preferred over 3 days.

We then compared the day-two harvest with $2.5 \mu\text{g DNA/ml}$ and transfection in the presence of 5%(v/v) FCS (2.5% final concentration) with the basic protocol ($1.25 \mu\text{g DNA/ml}$; no FCS; day-3 harvest; Fig. 3B). With this combination, genomic titers were not statistically different but the functional titer was 60% higher in the preparation with 2 days of growth.

We explain this observation with the fact that a higher quantity of starting DNA becomes more crucial if the cells grow for a shorter period of time; and whereas there is some toxicity when using higher amounts of PEI:DNA, the presence of serum seems to counteract. (We also performed an experiment with $2.5 \mu\text{g DNA/ml}$, where the serum was added after

Fig. 3 For each condition tested, cells were transfected in triplicates as described in Materials and Methods in a total volume of 4 ml using plasmids pHelper, pRepCap2, pAAV eGFP in a ratio of 2:1:1. Two or three days post-transfection, cells were harvested and virus isolated. Genomic titer was determined by RealTime PCR as described in Materials and Methods. Functional titer was determined by infecting adherent HEK 293 cells that have been transfected with pHelper; three days after infection, infected cells were lysed by two rounds of freeze-and-thaw, and the amount of GFP in the lysate was

quantified using a Cytofluor. Data are shown for our standard protocol (plasmids pHelper, pRepCap2, pAAV eGFP in a ratio of 2:1:1; growth in RPMI:Ex-Cell medium). Abbreviations: Day 2 (Harvest at day 2); day 3 (Harvest at day 3), 1× DNA (1.25 µg DNA/ml final concentration); 2× DNA (2.5 µg DNA/ml final concentration); 2.5% FCS (5% v/v FCS added during transfection, i.e., 2.5% v/v FCS final concentration). The data for 1× DNA and harvest at day 3 were set to 100% (with a functional titer of 3.5×10^{11} and a genomic titer of 9.1×10^{12} per liter of culture medium)

transfection; in that instance—independent of the growth period—we did not observe a positive effect of the serum.)

Comparison of AAV production in adherent cells (10% v/v FCS; calcium phosphate transfection) versus suspension cells (serum-free; PEI transfection)

After having established an optimized protocol for AAV production in suspension-adapted HEK 293 cells without the use of animal-derived products, such as serum or trypsin, we compared the yield to those obtained with the traditional protocol based on calcium phosphate mediated transfection of adherent HEK 293 cells in DMEM with 10%(v/v) FCS (see Materials and Methods and Auricchio et al. 2001). In order to compare the two methods, we used the medium as the common denominator, i.e., 1 l of medium for the suspension culture and 1 l of medium for the adherent culture, which corresponds to 50 15-cm dishes with 20 ml of medium each. However, we used twice as much DNA for the calcium phosphate transfection of adherent HEK 293 cells. The results are summarized in Table 1.

Our data indicate that the virus yields as well as infectivity are comparable in both systems. If one uses the amount of DNA as the common denominator, yields per mg of transfected DNA would be twice as high in the suspension system compared to the adherent system. Furthermore, yields for AAV2/5 vectors are higher than those for AAV2/2 vectors—independent of the system used. Given that both systems result in similar yields, the suspension system should be the method of choice given that it does not require animal-derived products, saves time and cost and can be easily scaled up or adapted to cGMP production.

Discussion

Summary of key findings

In this study, we presented a helper virus-free production method for AAV vectors in suspension-adapted HEK 293 cells without the use of animal-derived products, such as serum or trypsin. The method is based on plasmid transfection with 25 kDa linear polyethyleneimine (Baldi et al. 2005). Yields obtained with

Table 1 Comparison of adherent and suspension AAV production methods

Method	Serotype	Transgene	Scale	Genomic titer ^(a)	Functional titer ^(a)
Calcium phosphate transfection of adherent HEK 293 cells in DMEM with 10% FCS	AAV2	eGFP	50 15-cm plates	6.1×10^{12}	2.3×10^{11}
		e GFP	50 15-cm plates	1.1×10^{13}	3.5×10^{11}
		Luciferase	50 12-cm plates	4.8×10^{12}	n/a
	AAV5	eGFP	50 15-cm plates	1.3×10^{13}	3.2×10^9
		eGFP	50 15-cm plates	1.9×10^{13}	3.6×10^9
PEI transfection of suspension-adapted HEK 293 cells w/o animal-derived products	AAV2	eGFP	300 ml	8.7×10^{12}	3.1×10^{11}
		eGFP	900 ml	1.1×10^{13}	5.0×10^{11}
		Luciferase	900 ml	3.4×10^{12}	n/a
	AAV5	eGFP	300 ml	1.2×10^{13}	4.1×10^9
		eGFP	900 ml	1.6×10^{13}	3.7×10^9

^a Titers are shown as titer per liter of culture medium. Genomic titers were determined by RealTime PCR, functional titers by serial dilution as described in Materials and Methods

this system are comparable to those obtained with traditional production methods based on calcium phosphate mediated transfection of adherent HEK 293 cells in the presence of serum. The most important single factor for AAV yields in our system was the medium composition with a more than 5-fold impact on AAV titers. Increasing Cap ORF expression was the second most important lever (approximately factor 2 in the presence of serum). Cap expression is a rate-limiting step in AAV production (Vincent et al. 1997) and our data confirm these findings. The addition of serum alone had no major impact on yields, and its positive effect is most likely due to a dampening of PEI-toxicity during the transfection phase (Florea et al. 2002). Furthermore, cells should be harvested two days after transfection: Whereas the genomic titer is approximately 50% lower compared to a day three harvest, this effect is offset by a higher infectivity of the virus particles harvested at day two—leading to an overall efficacy increase of 30%.

Advantages of our protocol

Our AAV production protocol has several advantages over traditional HEK 293-based AAV production (see Table 2):

With our method, one can achieve—at the same time and without loss of AAV yield—scalability (suspension culture), GMP compliance/enablement (production without animal-derived products; no use of viruses in AAV production) and savings in terms of time, (material) cost and labor: As adherent HEK 293 cells are expanded by trypsinization and seeding of cells on a two-dimensional surface (e.g., tissue-culture flask), expansion, transfection and growth of adherent cells requires more time and labor cost compared to suspension cells. With suspension cells—independent of the scale—cells are propagated by determining cell density and resuspending the appropriate number of “old” cells in fresh medium. Moreover, we have grown the HEK 293 suspension cells in reusable glass bottles, whereas adherent cells require specially treated and expensive plastic surfaces to grow. Overall, material cost are about 40% lower and producing AAV in suspension-adapted HEK 293 cells takes only one fifth of the time compared to adherent HEK 293 culture.

Thus our protocol should appeal to both the basic research lab that wants to produce large quantities of AAV fast and cost effective, and industrial manufacturing units focusing on cGMP-compliant AAV production.

Table 2 Protocol flowchart and cost estimation

	Adherent HEK 293 cells			Suspension-adapted HEK 293 cells		
	Activity	Time	Cost (\$)	Activity	Time	Cost (\$)
Preparing cells for transfection	Splitting 10 15-cm plates to 30 plates, and 30 plates to 60 plates ⁽¹⁾	120 min ⁽²⁾	160 ⁽⁸⁾	Two cell splits with cell counting, centrifugation and cell resuspension	30 min ⁽⁵⁾	130 ⁽⁹⁾
Transfection	Calcium phosphate transfection with -Medium change -Transfection	100 min ⁽³⁾ 50 min ⁽⁴⁾	60 25 ⁽¹⁰⁾	PEI transfection including -Medium change -Transfection	15 min ⁽⁶⁾ 20 min ⁽⁶⁾	7 ⁽¹¹⁾ 13 ⁽¹⁰⁾
Medium change after transfection	Medium change the day after transfection	100 min ⁽³⁾	60	Addition of medium 4 hours after transfection	10 min	30
Cell harvest	Cell scraping and centrifugation	110 min ⁽⁷⁾		Centrifugation	10 min	
		480 min (8 hours)	\$305		85 min (~1.5 hours)	\$180

Numbers for calcium phosphate transfection of 50 15-cm tissue culture plates of adherent HEK 293 cells versus PEI transfection of 1 l (final volume) of suspension-adapted HEK 293 cells

(1) 50 plates for transfection; 10 plates to continue culture

(2) Assuming 3 min per plate; 40 plates to split

(3) Assuming 2 min per plate

(4) Assuming 1 min per plate

(5) Assuming 15 min for cell counting, centrifugation and resuspension

(6) Assuming one transfection cocktail and 500 ml volume transfection volume

(7) Assuming 2 min for scraping and 10 min for centrifugation

(8) 2 l of DMEM with 10% FCS (US\$60); 100 15-cm tissue culture plates (US\$100)

(9) 2 l of Ex-Cell medium (US\$120); US\$10 for glass bottles (recycling)

(10) US\$75 for 10 mg DNA (Qiagen Plasmid Giga Kit)

(11) US\$7 for 0.5 l RPMI 25 mM HEPES

Acknowledgement This work was financially supported by a KTI-grant obtained from the Swiss government.

References

Auricchio A, Hildinger M, O'Connor E, Gao GP, Wilson JM (2001) Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. *Hum Gene Ther* 12(1):71–76

Baldi L, Muller N, Picasso S, Jacquet R, Girard P, Thanh HP, Derow E, Wurm FM (2005) Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. *Biotechnol Prog* 21(1):148–153

Booth MJ, Mistry A, Li X, Thrasher A, Coffin RS (2004) Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids. *Gene Ther* 11(10):829–837

Brightwell G, Poirier V, Cole E, Ivins S, Brown KW (1997) Serum-dependent and cell cycle-dependent expression

- from a cytomegalovirus-based mammalian expression vector. *Gene* 194(1):115–123
- Conway JE, Rhys CM, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ (1999) High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. *Gene Ther* 6(6):986–993
- Durocher Y, Perret S, Thibaut E, Gaumont MH, Kamen A, Stocco R, Abramovitz M (2000) A reporter gene assay for high-throughput screening of G-protein-coupled receptors stably or transiently expressed in HEK293 EBNA cells grown in suspension culture. *Anal Biochem* 284(2):316–326
- Farson D, Harding TC, Tao L, Liu J, Powell S, Vimal V, Yendluri S, Koprivnikar K, Ho K, Twitty C, Husak P, Lin A, Snyder RO, Donahue BA (2004) Development and characterization of a cell line for large-scale, serum-free production of recombinant adeno-associated viral vectors. *J Gene Med* 6(12):1369–1381
- Florea BI, Meaney C, Junginger HE, Borchard G (2002) Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. *AAPS PharmSci* 4(3):E12
- Gao GP, Lu F, Sanmiguel JC, Tran PT, Abbas Z, Lynd KS, Marsh J, Spinner NB, Wilson JM (2002) Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. *Mol Ther* 5(5 Pt 1): 644–649
- Li C, Samulski RJ (2005) Serotype-specific replicating AAV helper constructs increase recombinant AAV type 2 vector production. *Virology* 335(1):10–21
- Li C, Bowles DE, van Dyke T, Samulski RJ (2005) Adeno-associated virus vectors: potential applications for cancer gene therapy. *Cancer Gene Ther*
- Liu X, Voulgaropoulou F, Chen R, Johnson PR, Clark KR (2000) Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. *Mol Ther* 2(4):394–403
- Mandel RJ, Burger C (2004) Clinical trials in neurological disorders using AAV vectors: promises and challenges. *Curr Opin Mol Ther* 6(5):482–490
- Maxwell F, Harrison GS, Maxwell IH (1997) Improved production of recombinant AAV by transient transfection of NB324K cells using electroporation. *J Virol Methods* 63(1–2):129–136
- Muller N, Girard P, Hacker DL, Jordan M, Wurm FM (2005) Orbital shaker technology for the cultivation of mammalian cells in suspension. *Biotechnol Bioeng* 89(4):400–406
- Samulski RJ (2003) AAV vectors, the future workhorse of human gene therapy. *Ernst Schering Res Found Workshop* (43):25–40
- Stratagene (2004) AAV Helper-Free System
- Urabe M, Ding C, Kotin RM (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors. *Hum Gene Ther* 13(16):1935–1943
- Vincent KA, Piraino ST, Wadsworth SC (1997) Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products. *J Virol* 71(3):1897–1905